 of Bulgaria provided information on April 8, stating that the Omicron variant has been discovered among 218 COVID-19 patients in the European nation. ){kind=link}
Sofia, Bulgaria: The National Centre for Infectious and Parasitic Diseases (NCIPD) of Bulgaria provided information on April 8, stating that the Omicron variant has been discovered among 218 COVID-19 patients in the European nation.
A total of 218 samples were taken in the time frame from March 17 to March 24, 2022, from at least 22 districts of Bulgaria, and each of them resulted in positive NCIPD states.
NCIPD further reveals that two patients of the novel coronavirus with Omicron variant died between March 15 to 29, 2022.
During same time frame, thirty-one (31) patients were in the hospital facilities, a total of 140 were under treatment, whereas a total of forty-five (45) patients got recovered from the deadliest virus, the data by NCIPD further reveals.
BA.2 subvariant of the Omicron strain was found among the 149 cases out of 218, which is almost 68.2% of all the samples. This percentage has been declined as compared to the previous percentage of 74.2, according to NCIPD.
The data adds that there were a total of forty-one (41) cases of the BA.1.1 subvariant; meanwhile, a total of forty-eight (48) samples confirmed BA.1 strain.
Below is the list of the districts where the specific number of the Omicron patients were discovered:
- Sofia (64),
- followed by the districts of Rousse (36),
- Plovdiv (22),
- Stara Zagora (15),
- Varna (13)
- and Bourgas (12).
On the other hand, at the present time, Bulgaria contains 169,884 active COVID-19 infections as of April 8, 2022, according to the official data. The total number of the COVID-19 related fatalities in Bulgaria stands at 36, 672.
Additionally, a finding was revealed by the United Kingdom researchers on Friday, stating that Omicron has a fewer risk of hospitalization as compared to the previous SARS-COV-2 variants such as – Delta. The study was done on the symptoms of 62,002 vaccinated individuals by the King’s College London and scientists of the ZOE COVID Study.